NDA 219285 · Genentech INC
Evrysdi
Risdiplam · Oral · Survival of Motor Neuron 2 Splicing Modifier
OrphanLast checked: Nov 20, 2026Latest source record: Sep 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Feb 11, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
22
4 Phase 3, 5 recruiting
FAERS reports
4,186
1,909 serious, 437 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 2, 2026.
EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. EVRYSDI is a survival of motor neuron 2 (SMN2) splicing modifier indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. ( 1 )
Mechanism: Risdiplam is a survival of motor neuron 2 (SMN2) splicing modifier designed to treat patients with spinal muscular atrophy (SMA) caused by mutations in chromosome 5q that lead to SMN protein deficiency. Using in vitro assays and studies in transgenic animal models of SMA, risdiplam was shown to increase exon 7 inclusion in SMN2 messenger ribonucleic acid (mRNA) transcripts and production of full-length SMN protein in the brain. In vitro and in vivo data indicate that risdiplam may cause alternative splicing of additional genes, including FOXM1 and MADD. FOXM1 and MADD are thought to be...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- EVRYSDI · RISDIPLAM 5MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Risdiplam" as an intervention, any sponsor and status, largest first.
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT05232929 · 403 participants · Start Mar 29, 2022 · Primary completion Oct 9, 2026
Drug: Risdiplam · For: Spinal Muscular Atrophy
Sites: Phoenix, Arizona; Little Rock, Arkansas; Loma Linda, California · 38 sites in all
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) ParticipantsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02908685 · 231 participants · Start Oct 19, 2016 · Primary completion Sep 6, 2019
Drug: Placebo; Risdiplam · For: Muscular Atrophy, Spinal
Sites: Palo Alto, California; New York, New York; Ghent, Belgium · 45 sites in all
- Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or RisdiplamPivotal-lookingCompleted
Scholar Rock, Inc.Industry
NCT05156320 · 188 participants · Start Apr 14, 2022 · Primary completion Dec 18, 2024
Drug: Apitegromab; Placebo · For: Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2 and 7 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 50 sites in all
- A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular AtrophyCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03032172 · 174 participants · Start Mar 3, 2017 · Primary completion Feb 7, 2025
Drug: Risdiplam · For: Spinal Muscular Atrophy
Sites: Palo Alto, California; Orlando, Florida; Boston, Massachusetts · 24 sites in all
- Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy ParticipantsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04718181 · 131 participants · Start Feb 1, 2021 · Primary completion Jan 28, 2023
Drug: risdiplam; omeprazole · For: Muscular Atrophy, Spinal
Sites: Daytona Beach, Florida; Springfield, Missouri; Dallas, Texas · 4 sites in all
- A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular AtrophyPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05115110 · 97 participants · Start Jun 2, 2022 · Primary completion Nov 2, 2026
Drug: RO7204239; Placebo and 1 more · For: Spinal Muscular Atrophy (SMA)
Sites: Boston, Massachusetts; New York, New York; Randwick, Australia · 29 sites in all
BiogenBiogen (BIIB)
NCT07444476 · 90 participants (planned) · Start Sep 8, 2026 · Primary completion Jun 23, 2028
Drug: Salanersen · For: Spinal Muscular Atrophy
Sites: Palo Alto, California; Boston, Massachusetts; Norfolk, Virginia · 12 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02913482 · 62 participants · Start Dec 23, 2016 · Primary completion Nov 14, 2019
Drug: Risdiplam · For: Muscular Atrophy, Spinal
Sites: Palo Alto, California; Chicago, Illinois; Boston, Massachusetts · 32 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- no adverse event356
- diarrhoea300
- asthenia230
- pneumonia225
- death215
- pyrexia186
- fatigue162
- vomiting149
- muscular weakness146
- drug ineffective140
- rash114
- headache111
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 3 |
| 2020 | 137 |
| 2021 | 594 |
| 2022 | 559 |
| 2023 | 698 |
| 2024 | 1,378 |
| 2025 | 483 |
| 2026 | 334 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Evrysdi (Risdiplam)
2024 spending
$155M
Beneficiaries
471
5,578 claims
Per beneficiary
$328,087
$165.95 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $15,161,292 |
| 2021 | $91,959,282 |
| 2022 | $120,799,423 |
| 2023 | $132,416,369 |
| 2024 | $154,528,772 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Risdiplam in Presymptomatic Spinal Muscular Atrophy.
Finkel RS, Servais L, Vlodavets D, et al. · N Engl J Med 2025 · Clinical Trial, Phase II, Multicenter Study
- Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial.
Crawford TO, Servais L, Mercuri E, et al. · Lancet Neurol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies.
Giess D, Erdos J, Wild C · Eur J Paediatr Neurol 2024 · Systematic Review
- RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.
Yu AM, Choi YH, Tu MJ · Pharmacol Rev 2020 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Risdiplam in Type 1 Spinal Muscular Atrophy.
Baranello G, Darras BT, Day JW, et al. · N Engl J Med 2021 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Combination therapies in spinal muscular atrophy: a systematic review.
Bemanalizadeh M, Heidary L, Dakkali MS, et al. · Eur J Pediatr 2025 · Systematic Review
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.